$1.710
+0.073 (+4.27%)收盤時
HCAT 資訊
HCAT 事件
Health Catalyst Closes Sale of Vitalware for $147 Million
Health Catalyst announced it closed the sale of Vitalware, through which the company conducted its Vitalware business, to Med-Metrix, a technology-enabled revenue cycle management company, on July 31. The transaction included $147M in total cash consideration for Health Catalyst, subject to customary adjustments. The company used those proceeds plus cash on hand to fully repay and retire its obligations under its credit facility, which eliminates approximately $19M in annual interest expense on a GAAP basis, based upon annualizing the first half of 2026.
Sees Q3 Adjusted EBITDA of $0-$500K
Sees Q3 adjusted EBITDA $0-$500K.
Company Reports Q2 Revenue of $70.49M, Exceeding Expectations
Reports Q2 revenue $70.49M, consensus $68.94M. The company recently closed the Vitalware divestiture and fully repaid its credit facility debt, which improves its balance sheet and provides flexibility. "We delivered a very productive second quarter, exceeding the high end of our revenue guidance and the midpoint of our adjusted EBITDA guidance," said CEO Ben Albert.
Sees FY26 Adjusted EBITDA of $18M to $18.5M
Sees FY26 adjusted EBITDA $18M to $18.5M.
Health Catalyst Divests Vitalware to Med-Metrix for $147M
Health Catalyst announced it has signed a definitive agreement to divest Vitalware and the Vitalware business unit, its mid-revenue cycle business, to Med-Metrix for a total consideration of $147M in cash.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。